ID   HERC2_HUMAN             Reviewed;        4834 AA.
AC   O95714; Q86SV7; Q86SV8; Q86SV9; Q86YY3; Q86YY4; Q86YY5; Q86YY6;
AC   Q86YY7; Q86YY8; Q86YY9; Q86YZ0; Q86YZ1;
DT   04-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-OCT-2010, sequence version 2.
DT   10-MAY-2017, entry version 152.
DE   RecName: Full=E3 ubiquitin-protein ligase HERC2;
DE            EC=2.3.2.26 {ECO:0000269|PubMed:20304803};
DE   AltName: Full=HECT domain and RCC1-like domain-containing protein 2;
DE   AltName: Full=HECT-type E3 ubiquitin transferase HERC2;
GN   Name=HERC2 {ECO:0000312|EMBL:AAD08657.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000312|EMBL:AAD08657.1}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9949213; DOI=10.1093/hmg/8.3.533;
RA   Ji Y., Walkowicz M.J., Buiting K., Johnson D.K., Tarvin R.E.,
RA   Rinchik E.M., Horsthemke B., Stubbs L., Nicholls R.D.;
RT   "The ancestral gene for transcribed, low-copy repeats in the Prader-
RT   Willi/Angelman region encodes a large protein implicated in protein
RT   trafficking, which is deficient in mice with neuromuscular and
RT   spermiogenic abnormalities.";
RL   Hum. Mol. Genet. 8:533-542(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:AAO27483.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2818-2895; 2909-2957; 2963-3290;
RP   3317-3363; 3389-3430; 3458-3495; 3512-3527; 3533-3633; 3635-3821;
RP   3826-4084; 4097-4505 AND 4529-4834, AND GENE STRUCTURE.
RX   PubMed=10720573; DOI=10.1101/gr.10.3.319;
RA   Ji Y., Rebert N.A., Joslin J.M., Higgins M.J., Schultz R.A.,
RA   Nicholls R.D.;
RT   "Structure of the highly conserved HERC2 gene and of multiple
RT   partially duplicated paralogs in human.";
RL   Genome Res. 10:319-329(2000).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2454 AND SER-2928, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [5]
RP   INVOLVEMENT IN SHEP1.
RX   PubMed=18252221; DOI=10.1016/j.ajhg.2007.10.003;
RA   Kayser M., Liu F., Janssens A.C.J.W., Rivadeneira F., Lao O.,
RA   van Duijn K., Vermeulen M., Arp P., Jhamai M.M., van Ijcken W.F.J.,
RA   den Dunnen J.T., Heath S., Zelenika D., Despriet D.D.G.,
RA   Klaver C.C.W., Vingerling J.R., de Jong P.T.V.M., Hofman A.,
RA   Aulchenko Y.S., Uitterlinden A.G., Oostra B.A., van Duijn C.M.;
RT   "Three genome-wide association studies and a linkage analysis identify
RT   HERC2 as a human iris color gene.";
RL   Am. J. Hum. Genet. 82:411-423(2008).
RN   [6]
RP   INVOLVEMENT IN SHEP1.
RX   PubMed=18252222; DOI=10.1016/j.ajhg.2007.11.005;
RA   Sturm R.A., Duffy D.L., Zhao Z.Z., Leite F.P.M., Stark M.S.,
RA   Hayward N.K., Martin N.G., Montgomery G.W.;
RT   "A single SNP in an evolutionary conserved region within intron 86 of
RT   the HERC2 gene determines human blue-brown eye color.";
RL   Am. J. Hum. Genet. 82:424-431(2008).
RN   [7]
RP   INVOLVEMENT IN SHEP1, AND REGULATION OF OCA2.
RX   PubMed=18172690; DOI=10.1007/s00439-007-0460-x;
RA   Eiberg H., Troelsen J., Nielsen M., Mikkelsen A., Mengel-From J.,
RA   Kjaer K.W., Hansen L.;
RT   "Blue eye color in humans may be caused by a perfectly associated
RT   founder mutation in a regulatory element located within the HERC2 gene
RT   inhibiting OCA2 expression.";
RL   Hum. Genet. 123:177-187(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2928; SER-4810; SER-4811
RP   AND SER-4814, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2454, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [11]
RP   MISCELLANEOUS.
RX   PubMed=20457063; DOI=10.1016/j.fsigen.2009.12.004;
RA   Mengel-From J., Borsting C., Sanchez J.J., Eiberg H., Morling N.;
RT   "Human eye colour and HERC2, OCA2 and MATP.";
RL   Forensic Sci. Int. Genet. 4:323-328(2010).
RN   [12]
RP   FUNCTION, INTERACTION WITH RNF8, PHOSPHORYLATION AT THR-4827,
RP   MUTAGENESIS OF THR-4827, AND SUBCELLULAR LOCATION.
RX   PubMed=20023648; DOI=10.1038/ncb2008;
RA   Bekker-Jensen S., Rendtlew Danielsen J., Fugger K., Gromova I.,
RA   Nerstedt A., Lukas C., Bartek J., Lukas J., Mailand N.;
RT   "HERC2 coordinates ubiquitin-dependent assembly of DNA repair factors
RT   on damaged chromosomes.";
RL   Nat. Cell Biol. 12:80-86(2010).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH XPA, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20304803; DOI=10.1073/pnas.0915085107;
RA   Kang T.H., Lindsey-Boltz L.A., Reardon J.T., Sancar A.;
RT   "Circadian control of XPA and excision repair of cisplatin-DNA damage
RT   by cryptochrome and HERC2 ubiquitin ligase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4890-4895(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2454 AND SER-2928, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-647; THR-1944 AND
RP   SER-2928, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   SUMOYLATION, FUNCTION, SUMO-BINDING, DOMAIN, INTERACTION WITH RNF8,
RP   AND MUTAGENESIS OF CYS-2708 AND CYS-2711.
RX   PubMed=22508508; DOI=10.1083/jcb.201106152;
RA   Danielsen J.R., Povlsen L.K., Villumsen B.H., Streicher W.,
RA   Nilsson J., Wikstrom M., Bekker-Jensen S., Mailand N.;
RT   "DNA damage-inducible SUMOylation of HERC2 promotes RNF8 binding via a
RT   novel SUMO-binding Zinc finger.";
RL   J. Cell Biol. 197:179-187(2012).
RN   [18]
RP   INTERACTION WITH CCP110; CEP97 AND NEURL4, AND SUBCELLULAR LOCATION.
RX   PubMed=22261722; DOI=10.1074/mcp.M111.014233;
RA   Al-Hakim A.K., Bashkurov M., Gingras A.C., Durocher D., Pelletier L.;
RT   "Interaction proteomics identify NEURL4 and the HECT E3 ligase HERC2
RT   as novel modulators of centrosome architecture.";
RL   Mol. Cell. Proteomics 11:M111.014233.01-M111.014233.14(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-272; SER-2454 AND
RP   SER-2928, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 417-790, AND RCC1 REPEATS.
RA   Tempel W., Khan M.B., Dong A., Hu J., Li Y., Bountra C.,
RA   Arrowsmith C.H., Edwards A.M., Tong Y.;
RT   "Structure of the first RCC1-like domain of HERC2.";
RL   Submitted (JUN-2013) to the PDB data bank.
RN   [21]
RP   VARIANT MRT38 LEU-594, AND CHARACTERIZATION OF VARIANT MRT38 LEU-594.
RX   PubMed=23065719; DOI=10.1002/humu.22237;
RA   Puffenberger E.G., Jinks R.N., Wang H., Xin B., Fiorentini C.,
RA   Sherman E.A., Degrazio D., Shaw C., Sougnez C., Cibulskis K.,
RA   Gabriel S., Kelley R.I., Morton D.H., Strauss K.A.;
RT   "A homozygous missense mutation in HERC2 associated with global
RT   developmental delay and autism spectrum disorder.";
RL   Hum. Mutat. 33:1639-1646(2012).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that regulates ubiquitin-
CC       dependent retention of repair proteins on damaged chromosomes.
CC       Recruited to sites of DNA damage in response to ionizing radiation
CC       (IR) and facilitates the assembly of UBE2N and RNF8 promoting DNA
CC       damage-induced formation of 'Lys-63'-linked ubiquitin chains. Acts
CC       as a mediator of binding specificity between UBE2N and RNF8.
CC       Involved in the maintenance of RNF168 levels. E3 ubiquitin-protein
CC       ligase that promotes the ubiquitination and proteasomal
CC       degradation of XPA which influences the circadian oscillation of
CC       DNA excision repair activity. {ECO:0000269|PubMed:20023648,
CC       ECO:0000269|PubMed:20304803, ECO:0000269|PubMed:22508508}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:20304803}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts (when phosphorylated at Thr-4827 and
CC       sumoylated) with RNF8 (via FHA domain); this interaction increases
CC       after ionizing radiation (IR) treatment. Interacts with XPA.
CC       Interacts with NEURL4. Via its interaction with NEURL4, may
CC       indirectly interact with CCP110 and CEP97.
CC       {ECO:0000269|PubMed:20023648, ECO:0000269|PubMed:20304803,
CC       ECO:0000269|PubMed:22261722, ECO:0000269|PubMed:22508508}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome, centriole. Nucleus.
CC       Note=Recruited to sites of DNA damage in response to ionizing
CC       radiation (IR) via its interaction with RNF8. May loose
CC       association with centrosomes during mitosis.
CC   -!- DOMAIN: The ZZ-type zinc finger mediates binding to SUMO1, and at
CC       low level SUMO2. {ECO:0000269|PubMed:22508508}.
CC   -!- DOMAIN: The RCC1 repeats are grouped into three seven-bladed beta-
CC       propeller regions. {ECO:0000269|PubMed:22508508}.
CC   -!- PTM: Phosphorylation at Thr-4827 is required for interaction with
CC       RNF8. {ECO:0000269|PubMed:20023648}.
CC   -!- PTM: Sumoylated with SUMO1 by PIAS4 in response to double-strand
CC       breaks (DSBs), promoting the interaction with RNF8.
CC       {ECO:0000269|PubMed:22508508}.
CC   -!- POLYMORPHISM: Genetic variants in HERC2 define the skin/hair/eye
CC       pigmentation variation locus 1 (SHEP1) [MIM:227220]; also known as
CC       skin/hair/eye pigmentation type 1, blue/nonblue eyes or
CC       skin/hair/eye pigmentation type 1, blue/brown eyes or
CC       skin/hair/eye pigmentation type 1, blond/brown hair or eye color,
CC       brown/blue or eye color, blue/nonblue or eye color type 3 (EYCL3)
CC       or brown eye color type 2 (BEY2) or hair color type 3 (HCL3).
CC       Hair, eye and skin pigmentation are among the most visible
CC       examples of human phenotypic variation, with a broad normal range
CC       that is subject to substantial geographic stratification. In the
CC       case of skin, individuals tend to have lighter pigmentation with
CC       increasing distance from the equator. By contrast, the majority of
CC       variation in human eye and hair color is found among individuals
CC       of European ancestry, with most other human populations fixed for
CC       brown eyes and black hair.
CC   -!- DISEASE: Mental retardation, autosomal recessive 38 (MRT38)
CC       [MIM:615516]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with
CC       impairments in adaptive behavior and manifested during the
CC       developmental period. MRT38 is characterized by global
CC       developmental delay affecting motor, speech, adaptive, and social
CC       development. Patients manifest autistic features, aggression,
CC       self-injury, impulsivity, and distractibility.
CC       {ECO:0000269|PubMed:23065719}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: A regulatory element withinin an intron of the
CC       HERC2 gene inhibits OCA2 promoter. There are several single
CC       nucleotide polymorphisms within the OCA2 gene and within the HERC2
CC       gene that have a statistical association with human eye color.
CC   -!- WEB RESOURCE: Name=Hect domain and RLD 2 (HERC2); Note=Leiden Open
CC       Variation Database (LOVD);
CC       URL="http://www.LOVD.nl/HERC2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF071172; AAD08657.1; -; mRNA.
DR   EMBL; AC091304; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC126332; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC135329; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF224243; AAO27473.1; -; Genomic_DNA.
DR   EMBL; AF224242; AAO27473.1; JOINED; Genomic_DNA.
DR   EMBL; AF224245; AAO27474.1; -; Genomic_DNA.
DR   EMBL; AF224244; AAO27474.1; JOINED; Genomic_DNA.
DR   EMBL; AF224249; AAO27475.1; -; Genomic_DNA.
DR   EMBL; AF224246; AAO27475.1; JOINED; Genomic_DNA.
DR   EMBL; AF224247; AAO27475.1; JOINED; Genomic_DNA.
DR   EMBL; AF224248; AAO27475.1; JOINED; Genomic_DNA.
DR   EMBL; AF224251; AAO27476.1; -; Genomic_DNA.
DR   EMBL; AF224250; AAO27476.1; JOINED; Genomic_DNA.
DR   EMBL; AF224255; AAO27479.1; -; Genomic_DNA.
DR   EMBL; AF224254; AAO27479.1; JOINED; Genomic_DNA.
DR   EMBL; AF224252; AAO27477.1; -; Genomic_DNA.
DR   EMBL; AF224253; AAO27478.1; -; Genomic_DNA.
DR   EMBL; AF224257; AAO27480.1; -; Genomic_DNA.
DR   EMBL; AF224256; AAO27480.1; JOINED; Genomic_DNA.
DR   EMBL; AF225401; AAO27481.1; -; Genomic_DNA.
DR   EMBL; AF225400; AAO27481.1; JOINED; Genomic_DNA.
DR   EMBL; AF225404; AAO27482.1; -; Genomic_DNA.
DR   EMBL; AF225402; AAO27482.1; JOINED; Genomic_DNA.
DR   EMBL; AF225403; AAO27482.1; JOINED; Genomic_DNA.
DR   EMBL; AF225407; AAO27483.1; -; Genomic_DNA.
DR   EMBL; AF225405; AAO27483.1; JOINED; Genomic_DNA.
DR   EMBL; AF225406; AAO27483.1; JOINED; Genomic_DNA.
DR   EMBL; AF225409; AAO27484.1; -; Genomic_DNA.
DR   EMBL; AF225408; AAO27484.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS10021.1; -.
DR   RefSeq; NP_004658.3; NM_004667.5.
DR   UniGene; Hs.434890; -.
DR   UniGene; Hs.610412; -.
DR   UniGene; Hs.741019; -.
DR   PDB; 2KEO; NMR; -; A=1203-1296.
DR   PDB; 3KCI; X-ray; 1.80 A; A=3951-4321.
DR   PDB; 4L1M; X-ray; 2.60 A; A/B/C=417-790.
DR   PDBsum; 2KEO; -.
DR   PDBsum; 3KCI; -.
DR   PDBsum; 4L1M; -.
DR   ProteinModelPortal; O95714; -.
DR   SMR; O95714; -.
DR   BioGrid; 114438; 234.
DR   DIP; DIP-37632N; -.
DR   IntAct; O95714; 34.
DR   MINT; MINT-8415335; -.
DR   STRING; 9606.ENSP00000261609; -.
DR   iPTMnet; O95714; -.
DR   PhosphoSitePlus; O95714; -.
DR   BioMuta; HERC2; -.
DR   EPD; O95714; -.
DR   MaxQB; O95714; -.
DR   PaxDb; O95714; -.
DR   PeptideAtlas; O95714; -.
DR   PRIDE; O95714; -.
DR   Ensembl; ENST00000261609; ENSP00000261609; ENSG00000128731.
DR   GeneID; 8924; -.
DR   KEGG; hsa:8924; -.
DR   UCSC; uc001zbj.5; human.
DR   CTD; 8924; -.
DR   DisGeNET; 8924; -.
DR   GeneCards; HERC2; -.
DR   GeneReviews; HERC2; -.
DR   H-InvDB; HIX0012044; -.
DR   H-InvDB; HIX0017540; -.
DR   H-InvDB; HIX0038121; -.
DR   H-InvDB; HIX0038320; -.
DR   H-InvDB; HIX0038830; -.
DR   H-InvDB; HIX0173226; -.
DR   H-InvDB; HIX0173299; -.
DR   H-InvDB; HIX0194348; -.
DR   HGNC; HGNC:4868; HERC2.
DR   HPA; CAB017188; -.
DR   HPA; HPA048389; -.
DR   MalaCards; HERC2; -.
DR   MIM; 227220; phenotype.
DR   MIM; 605837; gene.
DR   MIM; 615516; phenotype.
DR   neXtProt; NX_O95714; -.
DR   OpenTargets; ENSG00000128731; -.
DR   Orphanet; 329195; Developmental delay with autism spectrum disorder and gait instability.
DR   PharmGKB; PA29243; -.
DR   eggNOG; KOG1426; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   eggNOG; COG5184; LUCA.
DR   GeneTree; ENSGT00870000136376; -.
DR   HOVERGEN; HBG081598; -.
DR   InParanoid; O95714; -.
DR   KO; K10595; -.
DR   OMA; IMEMGFT; -.
DR   OrthoDB; EOG091G000E; -.
DR   PhylomeDB; O95714; -.
DR   TreeFam; TF320636; -.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; O95714; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; HERC2; human.
DR   EvolutionaryTrace; O95714; -.
DR   GeneWiki; HERC2; -.
DR   GenomeRNAi; 8924; -.
DR   PRO; PR:O95714; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000128731; -.
DR   ExpressionAtlas; O95714; baseline and differential.
DR   Genevisible; O95714; HS.
DR   GO; GO:0005814; C:centriole; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; NAS:UniProtKB.
DR   GO; GO:0032183; F:SUMO binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome.
DR   GO; GO:0006886; P:intracellular protein transport; NAS:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 2.30.30.30; -; 1.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 3.10.120.10; -; 1.
DR   InterPro; IPR004939; APC_su10/DOC_dom.
DR   InterPro; IPR006624; Beta-propeller_rpt_TECPR.
DR   InterPro; IPR021097; CPH_domain.
DR   InterPro; IPR001199; Cyt_B5-like_heme/steroid-bd.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR010606; Mib_Herc2.
DR   InterPro; IPR009091; RCC1/BLIP-II.
DR   InterPro; IPR000408; Reg_chr_condens.
DR   InterPro; IPR014722; Rib_L2_dom2.
DR   InterPro; IPR000433; Znf_ZZ.
DR   Pfam; PF03256; ANAPC10; 1.
DR   Pfam; PF11515; Cul7; 1.
DR   Pfam; PF00173; Cyt-b5; 1.
DR   Pfam; PF00632; HECT; 1.
DR   Pfam; PF06701; MIB_HERC2; 1.
DR   Pfam; PF00415; RCC1; 16.
DR   Pfam; PF00569; ZZ; 1.
DR   PRINTS; PR00633; RCCNDNSATION.
DR   SMART; SM01337; APC10; 1.
DR   SMART; SM01117; Cyt-b5; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SMART; SM00706; TECPR; 5.
DR   SMART; SM00291; ZnF_ZZ; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF50985; SSF50985; 3.
DR   SUPFAM; SSF55856; SSF55856; 1.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50255; CYTOCHROME_B5_2; 1.
DR   PROSITE; PS51284; DOC; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS51416; MIB_HERC2; 1.
DR   PROSITE; PS00626; RCC1_2; 1.
DR   PROSITE; PS50012; RCC1_3; 18.
DR   PROSITE; PS01357; ZF_ZZ_1; 1.
DR   PROSITE; PS50135; ZF_ZZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Coiled coil; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Disease mutation; DNA damage; DNA repair; Mental retardation;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Transferase; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1   4834       E3 ubiquitin-protein ligase HERC2.
FT                                /FTId=PRO_0000229739.
FT   REPEAT      415    461       RCC1 1-1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT      462    512       RCC1 1-2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT      513    568       RCC1 1-3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT      569    620       RCC1 1-4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT      623    674       RCC1 1-5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT      675    726       RCC1 1-6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT      728    778       RCC1 1-7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   DOMAIN     1207   1283       Cytochrome b5 heme-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00279}.
FT   DOMAIN     1859   1932       MIB/HERC2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00749}.
FT   DOMAIN     2759   2936       DOC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00614}.
FT   REPEAT     2958   3009       RCC1 2-1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     3010   3064       RCC1 2-2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     3065   3116       RCC1 2-3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     3118   3168       RCC1 2-4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     3171   3222       RCC1 2-5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     3224   3274       RCC1 2-6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     3275   3326       RCC1 2-7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     3951   4002       RCC1 3-1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     4004   4056       RCC1 3-2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     4058   4108       RCC1 3-3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     4110   4162       RCC1 3-4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     4164   4214       RCC1 3-5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     4216   4266       RCC1 3-6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   REPEAT     4268   4318       RCC1 3-7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00235, ECO:0000269|Ref.20}.
FT   DOMAIN     4457   4794       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   ZN_FING    2702   2749       ZZ-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00228}.
FT   COILED      948    980       {ECO:0000255}.
FT   ACT_SITE   4762   4762       Glycyl thioester intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00104}.
FT   MOD_RES     272    272       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     647    647       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1577   1577       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q4U2R1}.
FT   MOD_RES    1942   1942       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q4U2R1}.
FT   MOD_RES    1944   1944       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    2454   2454       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2928   2928       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    4810   4810       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    4811   4811       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    4814   4814       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    4827   4827       Phosphothreonine.
FT                                {ECO:0000269|PubMed:20023648}.
FT   VARIANT     594    594       P -> L (in MRT38; less stable than wild-
FT                                type; diffuse cytosolic localization with
FT                                the formation of abnormal aggregates;
FT                                dbSNP:rs397518474).
FT                                {ECO:0000269|PubMed:23065719}.
FT                                /FTId=VAR_069282.
FT   MUTAGEN    2708   2708       C->S: Abolishes binding to SUMO; when
FT                                associated with S-2711.
FT                                {ECO:0000269|PubMed:22508508}.
FT   MUTAGEN    2711   2711       C->S: Abolishes binding to SUMO; when
FT                                associated with S-2708.
FT                                {ECO:0000269|PubMed:22508508}.
FT   MUTAGEN    4827   4827       T->A: Prevents HERC2 C-terminal fragment
FT                                binding to endogenous RNF8.
FT                                {ECO:0000269|PubMed:20023648}.
FT   CONFLICT   1053   1053       L -> W (in Ref. 1; AAD08657).
FT                                {ECO:0000305}.
FT   CONFLICT   1150   1150       G -> D (in Ref. 1; AAD08657).
FT                                {ECO:0000305}.
FT   CONFLICT   1354   1354       S -> R (in Ref. 1; AAD08657).
FT                                {ECO:0000305}.
FT   CONFLICT   1566   1566       T -> M (in Ref. 1; AAD08657).
FT                                {ECO:0000305}.
FT   CONFLICT   1753   1753       K -> T (in Ref. 1; AAD08657).
FT                                {ECO:0000305}.
FT   CONFLICT   2444   2444       R -> H (in Ref. 1; AAD08657).
FT                                {ECO:0000305}.
FT   CONFLICT   2881   2881       C -> Y (in Ref. 1; AAD08657).
FT                                {ECO:0000305}.
FT   CONFLICT   3070   3070       S -> W (in Ref. 3; AAO27475).
FT                                {ECO:0000305}.
FT   CONFLICT   3346   3346       P -> R (in Ref. 3; AAO27476).
FT                                {ECO:0000305}.
FT   CONFLICT   3583   3584       VA -> MP (in Ref. 3; AAO27480).
FT                                {ECO:0000305}.
FT   CONFLICT   3597   3597       D -> N (in Ref. 3; AAO27480).
FT                                {ECO:0000305}.
FT   CONFLICT   3808   3808       F -> S (in Ref. 3; AAO27481).
FT                                {ECO:0000305}.
FT   STRAND      425    430       {ECO:0000244|PDB:4L1M}.
FT   TURN        436    438       {ECO:0000244|PDB:4L1M}.
FT   HELIX       446    449       {ECO:0000244|PDB:4L1M}.
FT   STRAND      453    458       {ECO:0000244|PDB:4L1M}.
FT   STRAND      460    467       {ECO:0000244|PDB:4L1M}.
FT   STRAND      472    476       {ECO:0000244|PDB:4L1M}.
FT   STRAND      495    499       {ECO:0000244|PDB:4L1M}.
FT   STRAND      505    511       {ECO:0000244|PDB:4L1M}.
FT   STRAND      516    520       {ECO:0000244|PDB:4L1M}.
FT   HELIX       523    525       {ECO:0000244|PDB:4L1M}.
FT   STRAND      528    531       {ECO:0000244|PDB:4L1M}.
FT   STRAND      535    540       {ECO:0000244|PDB:4L1M}.
FT   HELIX       542    544       {ECO:0000244|PDB:4L1M}.
FT   HELIX       549    551       {ECO:0000244|PDB:4L1M}.
FT   STRAND      552    558       {ECO:0000244|PDB:4L1M}.
FT   STRAND      560    567       {ECO:0000244|PDB:4L1M}.
FT   STRAND      572    576       {ECO:0000244|PDB:4L1M}.
FT   HELIX       579    581       {ECO:0000244|PDB:4L1M}.
FT   STRAND      585    587       {ECO:0000244|PDB:4L1M}.
FT   STRAND      591    596       {ECO:0000244|PDB:4L1M}.
FT   HELIX       598    600       {ECO:0000244|PDB:4L1M}.
FT   STRAND      605    610       {ECO:0000244|PDB:4L1M}.
FT   STRAND      616    621       {ECO:0000244|PDB:4L1M}.
FT   STRAND      626    630       {ECO:0000244|PDB:4L1M}.
FT   HELIX       633    635       {ECO:0000244|PDB:4L1M}.
FT   STRAND      638    642       {ECO:0000244|PDB:4L1M}.
FT   STRAND      645    650       {ECO:0000244|PDB:4L1M}.
FT   HELIX       652    654       {ECO:0000244|PDB:4L1M}.
FT   STRAND      659    665       {ECO:0000244|PDB:4L1M}.
FT   STRAND      668    673       {ECO:0000244|PDB:4L1M}.
FT   STRAND      678    682       {ECO:0000244|PDB:4L1M}.
FT   HELIX       685    687       {ECO:0000244|PDB:4L1M}.
FT   STRAND      691    693       {ECO:0000244|PDB:4L1M}.
FT   STRAND      697    702       {ECO:0000244|PDB:4L1M}.
FT   HELIX       704    706       {ECO:0000244|PDB:4L1M}.
FT   STRAND      711    716       {ECO:0000244|PDB:4L1M}.
FT   STRAND      718    725       {ECO:0000244|PDB:4L1M}.
FT   STRAND      730    735       {ECO:0000244|PDB:4L1M}.
FT   STRAND      746    754       {ECO:0000244|PDB:4L1M}.
FT   STRAND      763    768       {ECO:0000244|PDB:4L1M}.
FT   STRAND      770    777       {ECO:0000244|PDB:4L1M}.
FT   TURN        781    783       {ECO:0000244|PDB:4L1M}.
FT   HELIX      1212   1221       {ECO:0000244|PDB:2KEO}.
FT   STRAND     1225   1228       {ECO:0000244|PDB:2KEO}.
FT   STRAND     1231   1234       {ECO:0000244|PDB:2KEO}.
FT   HELIX      1235   1242       {ECO:0000244|PDB:2KEO}.
FT   HELIX      1250   1252       {ECO:0000244|PDB:2KEO}.
FT   HELIX      1257   1266       {ECO:0000244|PDB:2KEO}.
FT   HELIX      1270   1273       {ECO:0000244|PDB:2KEO}.
FT   HELIX      1274   1277       {ECO:0000244|PDB:2KEO}.
FT   STRAND     1278   1282       {ECO:0000244|PDB:2KEO}.
FT   HELIX      1285   1288       {ECO:0000244|PDB:2KEO}.
FT   STRAND     3954   3959       {ECO:0000244|PDB:3KCI}.
FT   STRAND     3971   3978       {ECO:0000244|PDB:3KCI}.
FT   HELIX      3980   3984       {ECO:0000244|PDB:3KCI}.
FT   STRAND     3987   3993       {ECO:0000244|PDB:3KCI}.
FT   STRAND     3996   4001       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4006   4010       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4013   4015       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4018   4022       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4025   4030       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4032   4034       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4039   4043       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4049   4055       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4060   4064       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4067   4069       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4073   4075       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4079   4084       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4086   4088       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4093   4098       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4100   4107       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4112   4116       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4119   4121       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4125   4127       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4131   4136       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4138   4140       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4145   4150       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4156   4161       {ECO:0000244|PDB:3KCI}.
FT   TURN       4162   4164       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4165   4170       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4173   4175       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4178   4181       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4185   4190       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4192   4194       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4199   4205       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4208   4213       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4218   4222       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4225   4227       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4231   4233       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4237   4242       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4244   4246       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4251   4256       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4258   4265       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4270   4274       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4283   4285       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4289   4294       {ECO:0000244|PDB:3KCI}.
FT   HELIX      4296   4298       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4305   4309       {ECO:0000244|PDB:3KCI}.
FT   STRAND     4312   4316       {ECO:0000244|PDB:3KCI}.
SQ   SEQUENCE   4834 AA;  527228 MW;  A323DC1DA6B221D0 CRC64;
     MPSESFCLAA QARLDSKWLK TDIQLAFTRD GLCGLWNEMV KDGEIVYTGT ESTQNGELPP
     RKDDSVEPSG TKKEDLNDKE KKDEEETPAP IYRAKSILDS WVWGKQPDVN ELKECLSVLV
     KEQQALAVQS ATTTLSALRL KQRLVILERY FIALNRTVFQ ENVKVKWKSS GISLPPVDKK
     SSRPAGKGVE GLARVGSRAA LSFAFAFLRR AWRSGEDADL CSELLQESLD ALRALPEASL
     FDESTVSSVW LEVVERATRF LRSVVTGDVH GTPATKGPGS IPLQDQHLAL AILLELAVQR
     GTLSQMLSAI LLLLQLWDSG AQETDNERSA QGTSAPLLPL LQRFQSIICR KDAPHSEGDM
     HLLSGPLSPN ESFLRYLTLP QDNELAIDLR QTAVVVMAHL DRLATPCMPP LCSSPTSHKG
     SLQEVIGWGL IGWKYYANVI GPIQCEGLAN LGVTQIACAE KRFLILSRNG RVYTQAYNSD
     TLAPQLVQGL ASRNIVKIAA HSDGHHYLAL AATGEVYSWG CGDGGRLGHG DTVPLEEPKV
     ISAFSGKQAG KHVVHIACGS TYSAAITAEG ELYTWGRGNY GRLGHGSSED EAIPMLVAGL
     KGLKVIDVAC GSGDAQTLAV TENGQVWSWG DGDYGKLGRG GSDGCKTPKL IEKLQDLDVV
     KVRCGSQFSI ALTKDGQVYS WGKGDNQRLG HGTEEHVRYP KLLEGLQGKK VIDVAAGSTH
     CLALTEDSEV HSWGSNDQCQ HFDTLRVTKP EPAALPGLDT KHIVGIACGP AQSFAWSSCS
     EWSIGLRVPF VVDICSMTFE QLDLLLRQVS EGMDGSADWP PPQEKECVAV ATLNLLRLQL
     HAAISHQVDP EFLGLGLGSI LLNSLKQTVV TLASSAGVLS TVQSAAQAVL QSGWSVLLPT
     AEERARALSA LLPCAVSGNE VNISPGRRFM IDLLVGSLMA DGGLESALHA AITAEIQDIE
     AKKEAQKEKE IDEQEANAST FHRSRTPLDK DLINTGICES SGKQCLPLVQ LIQQLLRNIA
     SQTVARLKDV ARRISSCLDF EQHSRERSAS LDLLLRFQRL LISKLYPGES IGQTSDISSP
     ELMGVGSLLK KYTALLCTHI GDILPVAASI ASTSWRHFAE VAYIVEGDFT GVLLPELVVS
     IVLLLSKNAG LMQEAGAVPL LGGLLEHLDR FNHLAPGKER DDHEELAWPG IMESFFTGQN
     CRNNEEVTLI RKADLENHNK DGGFWTVIDG KVYDIKDFQT QSLTGNSILA QFAGEDPVVA
     LEAALQFEDT RESMHAFCVG QYLEPDQEIV TIPDLGSLSS PLIDTERNLG LLLGLHASYL
     AMSTPLSPVE IECAKWLQSS IFSGGLQTSQ IHYSYNEEKD EDHCSSPGGT PASKSRLCSH
     RRALGDHSQA FLQAIADNNI QDHNVKDFLC QIERYCRQCH LTTPIMFPPE HPVEEVGRLL
     LCCLLKHEDL GHVALSLVHA GALGIEQVKH RTLPKSVVDV CRVVYQAKCS LIKTHQEQGR
     SYKEVCAPVI ERLRFLFNEL RPAVCNDLSI MSKFKLLSSL PRWRRIAQKI IRERRKKRVP
     KKPESTDDEE KIGNEESDLE EACILPHSPI NVDKRPIAIK SPKDKWQPLL STVTGVHKYK
     WLKQNVQGLY PQSPLLSTIA EFALKEEPVD VEKMRKCLLK QLERAEVRLE GIDTILKLAS
     KNFLLPSVQY AMFCGWQRLI PEGIDIGEPL TDCLKDVDLI PPFNRMLLEV TFGKLYAWAV
     QNIRNVLMDA SAKFKELGIQ PVPLQTITNE NPSGPSLGTI PQARFLLVML SMLTLQHGAN
     NLDLLLNSGM LALTQTALRL IGPSCDNVEE DMNASAQGAS ATVLEETRKE TAPVQLPVSG
     PELAAMMKIG TRVMRGVDWK WGDQDGPPPG LGRVIGELGE DGWIRVQWDT GSTNSYRMGK
     EGKYDLKLAE LPAAAQPSAE DSDTEDDSEA EQTERNIHPT AMMFTSTINL LQTLCLSAGV
     HAEIMQSEAT KTLCGLLRML VESGTTDKTS SPNRLVYREQ HRSWCTLGFV RSIALTPQVC
     GALSSPQWIT LLMKVVEGHA PFTATSLQRQ ILAVHLLQAV LPSWDKTERA RDMKCLVEKL
     FDFLGSLLTT CSSDVPLLRE STLRRRRVRP QASLTATHSS TLAEEVVALL RTLHSLTQWN
     GLINKYINSQ LRSITHSFVG RPSEGAQLED YFPDSENPEV GGLMAVLAVI GGIDGRLRLG
     GQVMHDEFGE GTVTRITPKG KITVQFSDMR TCRVCPLNQL KPLPAVAFNV NNLPFTEPML
     SVWAQLVNLA GSKLEKHKIK KSTKQAFAGQ VDLDLLRCQQ LKLYILKAGR ALLSHQDKLR
     QILSQPAVQE TGTVHTDDGA VVSPDLGDMS PEGPQPPMIL LQQLLASATQ PSPVKAIFDK
     QELEAAALAV CQCLAVESTH PSSPGFEDCS SSEATTPVAV QHIRPARVKR RKQSPVPALP
     IVVQLMEMGF SRRNIEFALK SLTGASGNAS SLPGVEALVG WLLDHSDIQV TELSDADTVS
     DEYSDEEVVE DVDDAAYSMS TGAVVTESQT YKKRADFLSN DDYAVYVREN IQVGMMVRCC
     RAYEEVCEGD VGKVIKLDRD GLHDLNVQCD WQQKGGTYWV RYIHVELIGY PPPSSSSHIK
     IGDKVRVKAS VTTPKYKWGS VTHQSVGVVK AFSANGKDII VDFPQQSHWT GLLSEMELVP
     SIHPGVTCDG CQMFPINGSR FKCRNCDDFD FCETCFKTKK HNTRHTFGRI NEPGQSAVFC
     GRSGKQLKRC HSSQPGMLLD SWSRMVKSLN VSSSVNQASR LIDGSEPCWQ SSGSQGKHWI
     RLEIFPDVLV HRLKMIVDPA DSSYMPSLVV VSGGNSLNNL IELKTININP SDTTVPLLND
     CTEYHRYIEI AIKQCRSSGI DCKIHGLILL GRIRAEEEDL AAVPFLASDN EEEEDEKGNS
     GSLIRKKAAG LESAATIRTK VFVWGLNDKD QLGGLKGSKI KVPSFSETLS ALNVVQVAGG
     SKSLFAVTVE GKVYACGEAT NGRLGLGISS GTVPIPRQIT ALSSYVVKKV AVHSGGRHAT
     ALTVDGKVFS WGEGDDGKLG HFSRMNCDKP RLIEALKTKR IRDIACGSSH SAALTSSGEL
     YTWGLGEYGR LGHGDNTTQL KPKMVKVLLG HRVIQVACGS RDAQTLALTD EGLVFSWGDG
     DFGKLGRGGS EGCNIPQNIE RLNGQGVCQI ECGAQFSLAL TKSGVVWTWG KGDYFRLGHG
     SDVHVRKPQV VEGLRGKKIV HVAVGALHCL AVTDSGQVYA WGDNDHGQQG NGTTTVNRKP
     TLVQGLEGQK ITRVACGSSH SVAWTTVDVA TPSVHEPVLF QTARDPLGAS YLGVPSDADS
     SAASNKISGA SNSKPNRPSL AKILLSLDGN LAKQQALSHI LTALQIMYAR DAVVGALMPA
     AMIAPVECPS FSSAAPSDAS AMASPMNGEE CMLAVDIEDR LSPNPWQEKR EIVSSEDAVT
     PSAVTPSAPS ASARPFIPVT DDLGAASIIA ETMTKTKEDV ESQNKAAGPE PQALDEFTSL
     LIADDTRVVV DLLKLSVCSR AGDRGRDVLS AVLSGMGTAY PQVADMLLEL CVTELEDVAT
     DSQSGRLSSQ PVVVESSHPY TDDTSTSGTV KIPGAEGLRV EFDRQCSTER RHDPLTVMDG
     VNRIVSVRSG REWSDWSSEL RIPGDELKWK FISDGSVNGW GWRFTVYPIM PAAGPKELLS
     DRCVLSCPSM DLVTCLLDFR LNLASNRSIV PRLAASLAAC AQLSALAASH RMWALQRLRK
     LLTTEFGQSI NINRLLGEND GETRALSFTG SALAALVKGL PEALQRQFEY EDPIVRGGKQ
     LLHSPFFKVL VALACDLELD TLPCCAETHK WAWFRRYCMA SRVAVALDKR TPLPRLFLDE
     VAKKIRELMA DSENMDVLHE SHDIFKREQD EQLVQWMNRR PDDWTLSAGG SGTIYGWGHN
     HRGQLGGIEG AKVKVPTPCE ALATLRPVQL IGGEQTLFAV TADGKLYATG YGAGGRLGIG
     GTESVSTPTL LESIQHVFIK KVAVNSGGKH CLALSSEGEV YSWGEAEDGK LGHGNRSPCD
     RPRVIESLRG IEVVDVAAGG AHSACVTAAG DLYTWGKGRY GRLGHSDSED QLKPKLVEAL
     QGHRVVDIAC GSGDAQTLCL TDDDTVWSWG DGDYGKLGRG GSDGCKVPMK IDSLTGLGVV
     KVECGSQFSV ALTKSGAVYT WGKGDYHRLG HGSDDHVRRP RQVQGLQGKK VIAIATGSLH
     CVCCTEDGEV YTWGDNDEGQ LGDGTTNAIQ RPRLVAALQG KKVNRVACGS AHTLAWSTSK
     PASAGKLPAQ VPMEYNHLQE IPIIALRNRL LLLHHLSELF CPCIPMFDLE GSLDETGLGP
     SVGFDTLRGI LISQGKEAAF RKVVQATMVR DRQHGPVVEL NRIQVKRSRS KGGLAGPDGT
     KSVFGQMCAK MSSFGPDSLL LPHRVWKVKF VGESVDDCGG GYSESIAEIC EELQNGLTPL
     LIVTPNGRDE SGANRDCYLL SPAARAPVHS SMFRFLGVLL GIAIRTGSPL SLNLAEPVWK
     QLAGMSLTIA DLSEVDKDFI PGLMYIRDNE ATSEEFEAMS LPFTVPSASG QDIQLSSKHT
     HITLDNRAEY VRLAINYRLH EFDEQVAAVR EGMARVVPVP LLSLFTGYEL ETMVCGSPDI
     PLHLLKSVAT YKGIEPSASL IQWFWEVMES FSNTERSLFL RFVWGRTRLP RTIADFRGRD
     FVIQVLDKYN PPDHFLPESY TCFFLLKLPR YSCKQVLEEK LKYAIHFCKS IDTDDYARIA
     LTGEPAADDS SDDSDNEDVD SFASDSTQDY LTGH
//
